Skip to main content

Table 1 Associations between receiving Chronic Myeloid Leukemia (CML) treatment initiation and patient characteristics

From: Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis

Characteristics 1998a 2004 2007
  n (%) χ2 OR p n (%) χ2 OR p n (%) χ2 OR p
   (p-value) (95%CI)b    (p-value) (95%CI)    (p-value) (95%CI)  
Age at diagnosis, years
   ≥40 228 (81.1) 9.16 (<0.01) 0.4 (0.2-0.8) <0.01 160 (74.4) 6.30 (0.01) 0.5 (0.2-0.9) 0.03 186 (72.1) 16.86 (<.0001) 0.4 (0.2-0.7) <0.01
   <40 53 (18.9)   1 (referent)   55 (25.6)   1 (referent)   72 (27.9)   1 (referent)  
Gender
   Male 166 (59.1) 0.00 (0.95) 0.8 (0.4-1.7) 0.60 126 (58.6) 1.25 (0.26) 0.7 (0.4-1.3) 0.26 151 (58.5) 0.49 (0.49) 1.4 (0.8-2.3) 0.29
   Female 115 (40.9)   1 (referent)   89 (41.4)   1 (referent)   107 (41.5)   1 (referent)  
Charlson comorbidity score
   ≥1 101 (35.9) 0.00 (0.97) 1.2 (0.6-2.4) 0.71 118 (54.9) 3.71 (0.05) 0.6 (0.4-1.2) 0.13 140 (54.3) 20.36 (<.0001) 0.4 (0.2-0.6) <0.001
   =0 180 (64.1)   1 (referent)   97 (45.1)   1 (referent)   118 (45.7)   1 (referent)  
CML severity
   high severity 45 (16.0) 17.90 (<.0001) 4.3 (2.0-9.3) <0.001 28 (13.0) 1.64 (0.20) 2.1 (0.8-5.4) 0.12 40 (15.5) 2.87 (0.09) 2.3 (1.1-5.1) 0.04
   less severity c 236 (84.0)   1 (referent)   187 (87.0)   1 (referent)   218 (84.5)   1 (referent)  
  1. a. 1998 (beginning of study, n = 281); 2004 (end of prior authorization request for imatinib use, n = 215); 2007 (end of study, n = 258).
  2. b. OR = odds ratio, each OR of the variable was adjusted by the other factors in the logistic regression model.
  3. c. Less severity, including moderate, low severity or missing relevant severity information (unknown).